Literature DB >> 1480508

C-type natriuretic peptide immunoreactivity in human breast vascular endothelial cells.

D M Heublein1, A L Clavell, A J Stingo, A Lerman, L Wold, J C Burnett.   

Abstract

The present study was undertaken to determine the presence of CNP immunoreactivity in human breast tissue (n = 9). Immunohistochemical staining of breast tissue revealed the presence of CNP immunoreactivity localized to vascular endothelial cells. This study demonstrates for the first time that CNP immunoreactivity is present in humans. Based upon the knows biological actions of CNP, these findings suggest that CNP may function as part of an endothelium-derived vasoregulatory system.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1480508     DOI： 10.1016/0196-9781(92)90065-b

Source DB:  PubMed          Journal:  Peptides        ISSN： 0196-9781            Impact factor:   3.750


  8 in total

1.  Circulating C-type natriuretic peptide and its relationship to cardiovascular disease in the general population.

Authors:  S Jeson Sangaralingham; Paul M McKie; Tomoko Ichiki; Christopher G Scott; Denise M Heublein; Horng H Chen; Kent R Bailey; Margaret M Redfield; Richard J Rodeheffer; John C Burnett
Journal:  Hypertension       Date:  2015-04-20       Impact factor: 10.190

2.  C-type natriuretic peptide does not attenuate the development of pulmonary hypertension caused by hypoxia and VEGF receptor blockade.

Authors:  Brian Casserly; Jeffrey M Mazer; Alexander Vang; Elizabeth O Harrington; James R Klinger; Sharon Rounds; Gaurav Choudhary
Journal:  Life Sci       Date:  2011-07-27       Impact factor: 5.037

3.  Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide.

Authors:  C M Wei; C H Kim; V M Miller; J C Burnett
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

4.  Direct chronotropic effects of atrial and C-type natriuretic peptides in anaesthetized dogs.

Authors:  P Beaulieu; R Cardinal; A De Léan; C Lambert
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

Review 5.  Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics.

Authors:  Sarah Mangiafico; Lisa C Costello-Boerrigter; Ingrid A Andersen; Alessandro Cataliotti; John C Burnett
Journal:  Eur Heart J       Date:  2012-08-31       Impact factor: 29.983

6.  PLASMA CONCENTRATIONS AND CORRELATIONS OF NATRIURETIC PEPTIDES AND OXYTOCIN DURING LABOR AND EARLY POSTPARTUM PERIOD.

Authors:  O F Ozer; O Kacar; O Demirci; Y S Eren; A S Bilsel
Journal:  Acta Endocrinol (Buchar)       Date:  2017 Jan-Mar       Impact factor: 0.877

Review 7.  Transient Receptor Potential Channels, Natriuretic Peptides, and Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure.

Authors:  Kun Ding; Yang Gui; Xu Hou; Lifang Ye; Lihong Wang
Journal:  Front Cardiovasc Med       Date:  2022-05-26

Review 8.  Atrial Natriuretic Peptide31-67: A Novel Therapeutic Factor for Cardiovascular Diseases.

Authors:  Gustavo Jose Justo da Silva; Raffaele Altara; George W Booz; Alessandro Cataliotti
Journal:  Front Physiol       Date:  2021-07-08       Impact factor: 4.566
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.